Critical Global Pandemic Safety Considerations: FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with C

June 29, 2020

On June 19, 2020, FDA released a Guidance for Industry (GFI) entitled Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing.

Previous Flipbook
COVID-19 and the new pragmatism
COVID-19 and the new pragmatism

Next Flipbook
COVID-19 Lay Summary EMA Management of Clinical Trials
COVID-19 Lay Summary EMA Management of Clinical Trials